Hims & Hers Health (HIMS) just switched on its Hers platform in Australia, giving women nationwide access to its personalised telehealth services in a market projected for rapid digital health growth.
For context, Hims & Hers Health shares now trade at US$30.64, and while the 30 day share price return of 11.38% and 7 day gain of 3.27% point to rebuilding momentum, the stock is still down over the past quarter and year to date, with a 1 year total shareholder return that has declined 44.02% even after very large gains over the past three and five years.
Compare how Hims & Hers Health stacks up against other digital health and telemedicine plays by reviewing our hand picked 33 healthcare AI stocks before you decide where momentum might build next.
Fresh Australian expansion on one side, a sharp 1 year share price decline on the other. Does it make more sense to lean into Hims & Hers Health at this point, or to insist on a cheaper entry and wait?
Most Popular Narrative: 82% Undervalued
On Simply Wall St, the most followed narrative now pegs Hims & Hers Health at a fair value of $171.19, far above the last close at $30.64. This frames the current share price as a steep discount in that view.
The thesis is not about one medication, one category or one quarter.
It is about a company repeatedly following the same playbook while expanding its addressable market.
More customers. More categories. More countries. More services per customer. Higher ARPU. Better operating leverage.
That is the Multi-Dimensional Growth Engine.
The combination of execution, expanding opportunity and improving economics suggests that the disconnect between Hims' underlying growth potential and current market pricing remains substantial, both in the short and long term.
See why 81 investors see Hims & Hers Health as 82% undervalued.
Result: Fair Value of $171.19 (UNDERVALUED)
Still, this story can break if international rollouts underperform expectations, or if weight loss partnerships shift in ways that weaken the broader Hims & Hers Health thesis.
Find out about the key risks to this Hims & Hers Health narrative.
Another View: What Hims & Hers Health’s Sales Multiple Is Telling You
The story shifts once you look at Hims & Hers Health through its P/S ratio. At 2.8x sales, the stock trades more expensively than both peers at 2.2x and the broader US Healthcare group at 1.3x, yet it is still below an estimated fair ratio of 4.6x. Is that a safety margin or a value trap forming?
To pressure test that question using a simple comparison tool, take a look at our breakdown of this valuation gap and what it could mean for future upside or downside risk, starting with the See what the numbers say about this price — find out in our valuation breakdown..
Here is how the current pricing compares visually with sector levels and the fair ratio anchor, using P/S as the yardstick, in
Next Steps
If this mix of optimism and caution around Hims & Hers Health feels familiar, treat it as your signal to move quickly, pull up the data, and stress test the story against your own expectations. To see how the positives stack up against the concerns in one place, review the 2 key rewards and 1 important warning sign
Looking for more investment ideas beyond Hims & Hers Health?
Use this Hims & Hers Health check as a springboard and keep building your watchlist with fresh ideas that fit your risk, income, and quality targets.
- Target potential bargains that pair solid fundamentals with appealing entry points by scanning our 29 high quality undervalued stocks.
- Lock in income-focused opportunities by reviewing a curated set of companies known for resilient payouts through the 8 dividend fortresses.
- Prioritise resilience and capital protection by reviewing a 31 resilient stocks with low risk scores that is designed to highlight businesses with stronger risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com